TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03532087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Description: Denosumab 120 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Description: Denosumab 60 mg every 6 months.
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 100 mg for CYP2D6 phenotyping
Description: Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 100 mg for CYP2D6 phenotyping
Description: Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
Study: NCT02770456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose fish oil
Description: Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 100 mg for CYP2D6 phenotyping
Description: Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
Study: NCT02770456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose fish oil
Description: Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
Study: NCT01341756

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy
Description: Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
Study: NCT03715582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimetazidine
Description: Pills of masking drug - trimetazidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Pills of masking drug - placebo
Study: NCT02784054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose radiotherapy
Study: NCT02844725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injections
Description: Colorless, transparent liquid in water for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study: NCT00433459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: drug is used in first line treatment in combination (COPP or COPDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: drug is used in first line treatment in combination (COPP or COPDAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: drug is used in first line treatment in combination (COPDAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procarbazine hydrochloride
Description: drug is used in first line treatment in combination (COPP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: used as a diagnostic marker for metabolically active tumour at staging and response assessment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fludeoxyglucose F 18
Description: used as a diagnostic marker for metabolically active tumour at staging and response assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: part of combination treatment (combined modality between chemo- and radiotherapy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: part of combination treatment (combined modality between chemo- and radiotherapy)
Study: NCT00987454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: 40,000 IU given as subcutaneous injection weekly up to 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: 1 m/L given as subcutaneous injection weekly up to 3 doses
Study: NCT04061447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility-guided therapy
Description: rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empirical clarithromycin-based triple therapy
Description: The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
Study: NCT00862147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICDP
Description: Parent training group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Parent and/or child focused interventions
Study: NCT01800084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asir Image Acquisition
Description: In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
Study: NCT00989131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclical®
Description: 250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxol®
Description: 175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
Study: NCT00202293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Study: NCT04262947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Vein Imaging
Description: Use of NI vein imaging device for visualization of veins during peripheral IV placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Vein Imaging
Description: Use of NI vein imaging device for visualization of veins during peripheral IV placement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV placement
Description: IV placement utilizing conventional methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional IV placement
Description: IV placement utilizing conventional methods
Study: NCT02464150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten challenge
Description: Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
Study: NCT02830945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention Arm

Intervention type: OTHER
Group type: OTHER
Intervention: Control Brochure Arm
Study: NCT01085266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon (latrepirdine)
Study: NCT02683005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir
Description: Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
Study: NCT02761876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor farmer training (Malawi)
Description: Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor farmer training (Singida, Tanzania)
Description: Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor farmer visits and facilitation
Description: Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
Study: NCT02442154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Description: It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
Study: NCT04499820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrof
Description: DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meralut
Description: vitamin A, natural flavonoids, lutein and zeaxanthin
Study: NCT04088487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New in Town-Interner Intervention for Migrants
Description: New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: New in Town-Interner Intervention for Migrants
Description: New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
Study: NCT00932113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: 2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: 2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
Study: NCT04032587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)
Description: First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)
Description: First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based interventions (e.g. body scan)
Description: Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (e.g. body scan)
Description: Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
Study: NCT04312893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture (Press Tack Needle)
Description: Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: press tack placebo
Description: press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
Study: NCT01481220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
Study: NCT02148549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIRINOX
Description: FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
Study: NCT04360317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of SH003 and Docetaxel
Description: Combination of SH003 and Docetaxel
Study: NCT04778241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
Study: NCT02050711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 100 mg for CYP2D6 phenotyping
Description: Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Single-dose of simvastatin 40 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Single-dose of simvastatin 40 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Single-dose of simvastatin 40 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
Study: NCT03898401

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
Study: NCT01251185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiospec
Description: Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
Study: NCT02273817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal spray, 50 μg per actuation.
Description: During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal spray, 50 μg per actuation.
Description: During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide nasal spray, 50 μg per actuation.
Description: During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.